Innoviva (INVA) Q3 2026 earnings review
Innoviva's hospital drug sales jump, but investment losses erase profit
Innoviva, a drugmaker that collects inhaler royalties and sells hospital antibiotics, grew its U.S. drug business while its investment portfolio lost value. Domestic drug sales jumped 45% to $43 million and lifted operating profit 22%, even though lower royalties and foreign shipments pulled total revenue down slightly. Chief executive Pavel Raifeld kept the full-year U.S. drug sales target at $150 million or more, which by our math requires only 6% growth in the fourth quarter.
| U.S. net product sales | $43.3M +45% from a year ago |
|---|---|
| Gross royalty revenue | $58.1M -8% from a year ago |
| Operating profit | $42.2M +22% from a year ago |
| Full-year U.S. product sales outlook | Unchanged at least $150M (+26% from 2025) |
⚖️ Verdict: 🟢 Bullish
The story got better because the hospital drug division proved it can expand operating profit faster than inhaler royalties decline. Medical society treatment rules now favor its pneumonia drug Xacduro, and the new oral gonorrhea antibiotic Nuzolvence reached the U.S. market on schedule. One caution: a $140 million markdown on outside biotech holdings, led by Armata Pharmaceuticals, pushed the bottom line into a net loss for a second straight quarter.
The question now is whether expanding hospital drug profits or volatile biotech investments and shrinking royalties will define future earnings. If hospital drugs dominate, operating cash flow will grow steadily and fund more share buybacks; if Armata keeps falling while royalties slip, balance sheet losses will keep erasing operating gains. Fourth-quarter prescription traction for Nuzolvence and year-end portfolio valuations will tell.
🐂 Bull Case
U.S. Hospital Drug Sales Accelerated to 45% Growth
Innoviva Specialty Therapeutics (IST), the division selling hospital critical care and infectious disease drugs, accelerated its domestic growth. U.S. net product sales jumped 44.8% from a year ago to $43.3 million, speeding up from 26.0% growth in the second quarter. Chief executive Pavel Raifeld said the quarter was "keeping us on track to achieve our 2026 guidance of at least $150 million in U.S. net product sales".
- Xacduro, an intravenous antibiotic for hospital bacterial pneumonia: $16.1 million in U.S. sales, up 89.4% from a year ago by our math
- Giapreza, an intravenous drug to raise blood pressure in septic shock: $23.1 million in U.S. sales, up 26.9% by our math
- Xerava, an antibiotic for complicated abdominal infections: $3.4 million in U.S. sales, up 6.3% by our math
- International product sales: $6.1 million, down 64.9% by our math due to "fluctuations in the timing of inventory sales to ex-U.S. partners"
Clinical backing is helping Xacduro gain hospital accounts. The Infectious Diseases Society of America updated its treatment rules to reaffirm Xacduro as the preferred choice for resistant infections, while relegating older combination drugs to "temporary bridging therapy" when Xacduro is unavailable. Because the U.S. business reached $114.1 million in the first nine months by our math, it needs only $35.9 million in the fourth quarter to clear the full-year target.
What to watch: fourth-quarter U.S. sales of Xacduro and Giapreza, alongside initial prescription orders for the newly launched antibiotic Nuzolvence. Continued sequential gains above $43.3 million would show that the updated medical guidelines are pulling Xacduro into more hospital formularies.
Operating Profit Rose 22% as Drug Margins Improved
Operating profit grew 21.9% from a year ago to $42.2 million even though total revenue slipped 1.6% to $106.1 million. By our math, operating margin expanded by 7.7 percentage points to 39.7%. Two cost lines drove the improvement: cost of products sold, which is the expense of manufacturing drugs and writing down acquired inventory step-ups, and research and development spending.
By our math, cost of products sold fell by 9.6 percentage points of revenue to 14.2%, while research and development fell by 7.8 percentage points to 4.9% as prior-year trial costs rolled off. That savings covered a 9.6 percentage point rise in selling, general and administrative expenses to 34.9% of revenue, which the company tied to the "expansion of commercial activities to support future sales growth".
What to watch: selling, general and administrative expense as a share of revenue in the fourth quarter. A leveling off from 34.9% would verify Raifeld's claim that sales force expansion will yield operating leverage as new antibiotics scale.
Buybacks Have Retired Over 5% of the Company
Innoviva bought back 1.23 million shares for $26.3 million during the third quarter under its $125 million repurchase authorization. Since starting the program in late 2025, the drugmaker has retired 3.83 million shares for $82.7 million, using 66.2% of the total allowance by our math. That steady buying lowered the basic share count by 1.8% from last quarter to 72.1 million.
What to watch: whether the board authorizes a new repurchase program once the remaining $42.3 million is spent. At the recent pace of $20 million to $31 million per quarter, the current allowance will run out within two quarters.
🐻 Bear Case
Inhaler Royalties Fell 8% Despite 'Stable' Framing
Innoviva collects royalties from partner Glaxo Group Limited (GSK) on global sales of respiratory inhalers Relvar, Breo Ellipta, and Anoro Ellipta. In its financial highlights, the company wrote that "gross royalty revenue from Glaxo Group Limited (“GSK”) remained stable at $58.1 million". That wording obscures a steady year-over-year contraction in the company's highest-margin cash stream.
While $58.1 million is close to the $58.6 million recorded in the first quarter and $59.8 million in the second quarter, it fell 8.3% from $63.4 million in the third quarter of last year by our math. After subtracting $3.5 million in fee amortization, net royalty revenue dropped 8.7% from a year ago to $54.7 million, and is down 8.5% over the first nine months of 2026.
This erosion matters because royalties carry no manufacturing or sales force expenses, funding both the hospital drug buildout and share buybacks. In the third quarter, the $5.2 million drop in net royalties combined with an $11.3 million drop in international partner shipments to pull total revenue down 1.6%, completely masking the $13.4 million domestic hospital drug gain.
What to watch: fourth-quarter gross royalties from GSK against the $58.4 million recorded in the fourth quarter of 2025. A fifth straight year-over-year decline would show that inhaler pricing or volume pressure is a permanent drag on top-line growth.
Biotech Stock Bets Erased Three Quarters of Profit
Alongside its drug and royalty operations, Innoviva holds a portfolio of equity and debt stakes in other healthcare companies valued at $535.5 million at quarter-end. During the third quarter, the biopharmaceutical group booked $139.5 million in net unrealized fair value losses on these holdings, which it attributed to a "decline in the stock price of Armata Pharmaceuticals at quarter-end".
That markdown followed a $161.0 million portfolio loss in the second quarter, swinging third-quarter bottom-line results from an $89.9 million profit a year ago to a $73.9 million net loss ($1.03 per share). For the first nine months of 2026, $109.3 million in cumulative investment write-downs wiped out most of the $131.2 million earned from operations, leaving just $29.3 million in net income.
Concentration risk remains high even after two quarters of markdowns. Armata Pharmaceuticals still makes up $323.7 million, or 60.4% of the $535.5 million investment portfolio by our math, down from $603.4 million at the end of March. Because GAAP rules require quarterly mark-to-market accounting, swings in a single thinly traded biotechnology holding dictate reported earnings.
What to watch: any new cash commitments to Armata or other portfolio companies in the fourth quarter, after nine-month investing cash outflows reached $23.7 million. Adding more capital to concentrated positions would increase balance sheet exposure rather than returning cash to shareholders.
👓 Other Themes
NUZOLVENCE Reached the U.S. Market on Schedule
Innoviva launched Nuzolvence (zoliflodacin), a single-dose oral antibiotic for uncomplicated urogenital gonorrhea, in the United States during the third quarter. The Centers for Disease Control and Prevention listed drug-resistant gonorrhea in its highest threat category in 2026. The company said initial commercial work is focused on "establishing market access, distribution and dispensing infrastructure" so patients can fill prescriptions and build adoption over time.
💲 Other KPIs
Cash rose from $570.4 million in the second quarter and $550.9 million at year-end, even after spending $26.3 million on share buybacks in the third quarter. Against $258.8 million in convertible notes due in 2028, Innoviva holds $322.6 million in net cash by our math.
Receivables — money owed by GSK for royalties and by wholesalers for drug shipments — fell from $110.6 million last quarter, but rose 9.2% from a year ago by our math against a 1.6% dip in total revenue. Nine-month operating cash flow was $129.0 million, implying $41.7 million in the third quarter by our math.
Inventory climbed 9.9% from $39.0 million in the second quarter and 11.7% from $38.4 million a year ago by our math. The biopharmaceutical company built stock to support expanding U.S. hospital demand for Xacduro and Giapreza alongside the commercial rollout of Nuzolvence.
🔮 Guidance
Unchanged. The full-year plan still calls for at least $150 million in U.S. hospital drug sales, up at least 25.8% from $119.2 million in 2025 by our math. Because U.S. sales already reached $114.1 million through September, the floor leaves just $35.9 million for the fourth quarter (5.9% growth from a year ago and a 17.1% drop from the third quarter), making the target easy to clear.
❓ Key Questions
Why keep the $150 million U.S. sales floor unchanged?
U.S. net product sales totaled $114.1 million in the first nine months by our math, leaving only $35.9 million in the fourth quarter to reach $150 million. Did management hold the floor out of caution, or do they expect hospital ordering to slow?
What were third-quarter sales for Zevtera and Nuzolvence?
Giapreza ($23.1 million), Xacduro ($16.1 million), and Xerava ($3.4 million) accounted for $42.6 million of the $43.3 million in U.S. product sales, leaving $0.7 million for Zevtera and Nuzolvence combined. When will Innoviva break out revenue for these two antibiotics?
When will international partner shipments normalize?
Ex-U.S. product sales dropped to $6.1 million from $15.2 million in the second quarter and $17.4 million a year ago on partner inventory timing. What is the baseline quarterly run-rate for international shipments once partner restocking evens out?
Will Innoviva cap its capital exposure to Armata Pharmaceuticals?
Armata still represents 60.4% of the $535.5 million healthcare investment portfolio by our math, and its stock drop drove $300.5 million in combined portfolio markdowns over the last two quarters. Will the board limit further cash infusions into Armata?